Search research articles
Contact Us
Filters
Showing results (11-20 of 87) with videos related to
Page
of 9
Sort By:
Lancet (London, England)
|
May 27, 2015
An alternative combination therapy for type 2 diabetes?
Signe H Østoft, Mikkel Christensen
Current Diabetes Reports
|
April 29, 2010
Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide?
Mikkel Christensen, Filip K Knop
British Journal of Clinical Pharmacology
|
July 19, 2016
Hypoglycaemia when adding sulphonylurea to metformin: a systematic review and network meta-analysis
Stig Ejdrup Andersen, Mikkel Christensen
Nucleic Acids Research
|
October 16, 2008
Translation affects YoeB and MazF messenger RNA interferase activities by different mechanisms
Mikkel Christensen-Dalsgaard, Kenn Gerdes
Diabetes
|
August 28, 2012
Comment on: Gögebakan et al. Glucose-dependent insulinotropic polypeptide reduces fat-specific expression and activity of 11β-hydroxysteroid dehydrogenase type 1 and inhibits release of free fatty acids. Diabetes 2012;61:292-300
Filip K Knop, Mikkel Christensen
Lancet (London, England)
|
January 10, 2012
The unobtainable placebo: control of independent clinical research by industry?
Mikkel Christensen, Filip K Knop
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy
|
July 5, 2013
Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus
Andreas B Petersen, Mikkel Christensen
Ugeskrift for Laeger
|
February 16, 2011
[Colonic malacoplakia treated with sulfamethizole and trimethoprim]
Mikkel Christensen, Svend Knuhtsen, Elisabeth Knudsen
Ugeskrift for Laeger
|
October 28, 2023
Mikkel Christensen, Cille Bülow, Andreas Lundh
Ugeskrift for Laeger
|
March 20, 2015
[Pharmaceutical drugs containing lactose can as a rule be used by persons with lactose intolerance]
Siri Vinther, Jöri Johannes Rumessen, Mikkel Christensen
Page
of 9
Search research articles
Search
Showing results (11-20 of 87) with videos related to
Sort By:
Page
of 9
Lancet (London, England)
|
May 27, 2015
An alternative combination therapy for type 2 diabetes?
Signe H Østoft, Mikkel Christensen
Current Diabetes Reports
|
April 29, 2010
Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide?
Mikkel Christensen, Filip K Knop
British Journal of Clinical Pharmacology
|
July 19, 2016
Hypoglycaemia when adding sulphonylurea to metformin: a systematic review and network meta-analysis
Stig Ejdrup Andersen, Mikkel Christensen
Nucleic Acids Research
|
October 16, 2008
Translation affects YoeB and MazF messenger RNA interferase activities by different mechanisms
Mikkel Christensen-Dalsgaard, Kenn Gerdes
Diabetes
|
August 28, 2012
Comment on: Gögebakan et al. Glucose-dependent insulinotropic polypeptide reduces fat-specific expression and activity of 11β-hydroxysteroid dehydrogenase type 1 and inhibits release of free fatty acids. Diabetes 2012;61:292-300
Filip K Knop, Mikkel Christensen
Lancet (London, England)
|
January 10, 2012
The unobtainable placebo: control of independent clinical research by industry?
Mikkel Christensen, Filip K Knop
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy
|
July 5, 2013
Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus
Andreas B Petersen, Mikkel Christensen
Ugeskrift for Laeger
|
February 16, 2011
[Colonic malacoplakia treated with sulfamethizole and trimethoprim]
Mikkel Christensen, Svend Knuhtsen, Elisabeth Knudsen
Ugeskrift for Laeger
|
October 28, 2023
Mikkel Christensen, Cille Bülow, Andreas Lundh
Ugeskrift for Laeger
|
March 20, 2015
[Pharmaceutical drugs containing lactose can as a rule be used by persons with lactose intolerance]
Siri Vinther, Jöri Johannes Rumessen, Mikkel Christensen
Page
of 9